News

Latest news

24th March 2023

Acticor Biotech publishes its 2022 annual results and provides an update on its clinical progress

22nd March 2023

Nikkei Bio Article: AMED's Drug Discovery Venture Ecosystem Enhancement Project Selected for the First Time by Two Companies - Edit Force and Immunohelix

22nd March 2023

EditForce, Inc. announced that our "Development of an Innovative Treatment for Myotonic Dystrophy Type 1 by a Sequence--Specific RNA Binding Protein Targeting Pathogenic CUG Repeat

22nd March 2023

EditForce, Inc. (Headquarter: Fukuoka, President and CEO: Takashi Ono) announces that we have raised a total of 1.8 billion yen through a third-party allotment of new shares by March 22, 2023.

Acticor Biotech successfully completes a capital increase for a total gross amount of 12.2 million euros, via the issuance of 1,793,005 shares

Sequana Medical announces positive results from CHIHUAHUA, Phase 1 clinical trial of second-generation DSR product for congestive heart failure

Certified VC interview Newton Biocapital Partners Sadashi Suzuki by Medical Innovation Support Office (MEDISO) - Japanese Ministry of Health and Labour

8th February 2023

Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure

3rd February 2023

インタビュー記事掲載のお知らせ「2月3日の日経バイオテクに当社クリニカル＆メディカルサイエンス・和田道彦と、日本代表・鈴木貞史の記事が掲載されました。タイトルは、「ベルギーNewton Biocapital社幹部に聞く、日本のシーズを世に出すには？」

1
2
3